Anzeige
Mehr »
Freitag, 25.07.2025 - Börsentäglich über 12.000 News
Richtig investiert verwandelt der Goldpreis jeden Euro in glänzendes Vermögen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
162 Leser
Artikel bewerten:
(1)

Patient Registry Software Market worth $3.61 billion by 2030 with 9.8% CAGR | MarketsandMarkets

DELRAY BEACH, Fla., July 24, 2025 /PRNewswire/ -- The global Patient Registry Software Market, valued at US$2.06 billion in 2024 stood at US$2.25 billion in 2025 and is projected to advance at a resilient CAGR of 9.8% from 2025 to 2030, culminating in a forecasted valuation of US$3.61 billion by the end of the period. The robust growth in registry software solutions is driven by a focus on patient-centric care and value-based healthcare delivery. Due to their flexibility and cost-effectiveness, the demand for public databases and cloud-based models is increasing. Government initiatives like the US CMS's Quality Payment Program and the EU's Horizon Health projects are accelerating adoption. Additionally, strategic partnerships and data modernization enhance interoperability and cross-platform sharing, fostering further innovation in this field.

MarketsandMarkets Logo

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=144694594

Browse in-depth TOC on "Patient Registry Software Market"

150 - Tables
50 - Figures
360 - Pages

By registry type, the patient registry software market is categorized by registry type into two main segments: disease registries and product registries. The disease registries segment includes various types such as diabetes registries, cardiovascular registries, cancer registries, rare disease registries, asthma registries, chronic kidney disease registries, and orthopaedic registries. There are also registries for other conditions, including ophthalmology, hemophilia, COVID-19, and neuromuscular diseases.

In 2025, the disease registries segment held the largest share of the patient registry software market. This dominance is primarily due to the increasing prevalence of chronic and rare diseases. According to Rare Diseases International (RDI), by 2025, over 300 million people worldwide will be living with a rare disease, which accounts for 3.5% to 5.9% of the global population. This rise in cases boosts the demand for disease registries, as they facilitate early diagnosis, enhance clinical research, and support the development of targeted therapies by providing structured, real-world data on chronic and rare disease populations.

By Deployment Model, Growth in this market segment can be mainly attributed to the reliability, accuracy, and clinical depth of the data recorded by healthcare professionals at the point of care. Hospitals, academic medical centers, and specialty clinics widely adopt these registries to capture structured patient information for outcome tracking, treatment benchmarking, and longitudinal studies. The increasing focus on evidence-based medicine, regulatory compliance, and quality reporting has driven the demand for provider-entered registries. Additionally, integration with electronic health record (EHR) systems allows for the automatic population of clinical fields, which enhances data quality and reduces administrative overhead. Leading registry initiatives, such as the American College of Cardiology's National Cardiovascular Data Registry (NCDR) and the American Society of Clinical Oncology's CancerLinQ, utilize site-based registries to provide national-level insights into disease trends, treatment effectiveness, and real-world patient outcomes.

By geography, The Asia Pacific patient registry software market is set to experience significant growth due to advancements in digital health infrastructure, increased clinical research, and rising government investments in healthcare IT, particularly in countries like India, China, Japan, and South Korea. For example, India launched a rare disease patient registry in January 2025 to improve diagnosis and care. In 2022, China's NMPA updated guidelines for medical device software registration, aiding market entry. With large patient populations and growing pharmaceutical R&D outsourcing, there is a high demand for real-world evidence and specific registries. Local regulatory reforms and enhanced collaborations are further driving adoption, making the Asia Pacific a key area for scalable, tech-enabled patient registry solutions.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=144694594

The main companies operating in the patient registry software market include IBM (US), IQVIA Holdings Inc. (US), Health Catalyst Inc. (US), Oracle (US), UnitedHealth Group (US), Conduent Inc. (US), and Elekta (Sweden).

IBM (US)

IBM has established a strong presence in the global patient registry software market due to its advanced healthcare data management solutions. Its flagship platform, InfoSphere Master Data Management (MDM) for healthcare, is widely adopted for managing patient and provider information across complex healthcare ecosystems. The platform supports data standardization, governance, and interoperability, which are essential for building reliable and scalable patient registries. Recently, IBM enhanced the platform with version 14.0, which introduced improved compliance features, real-time data integration, and advanced analytics capabilities. These updates cater to the needs of value-based care and population health programs. IBM's partnerships with hospitals, government agencies, and private payers around the world, along with its presence in 175 countries, reinforce its role as a digital backbone in healthcare transformation. The solutions provided by IBM enable healthcare stakeholders to streamline patient identity resolution, enhance care coordination, and derive insights for clinical research and policymaking.

IQVIA Holdings Inc. (US)

IQVIA Holdings Inc. (US) is a leading provider of clinical and real-world data solutions, driving innovation in the patient registry software market with its integrated platforms and extensive expertise in life sciences. The company offers two main products: Patient Registry Solutions and the Clinical Insight Platform. These tools are designed to leverage real-world data for clinical trials, epidemiological studies, and long-term disease surveillance. IQVIA's registries support both patient-reported and clinician-reported outcomes, which enhance research quality and ensure regulatory compliance. The platforms are highly customizable, compliant with GDPR, and capable of supporting multinational studies with diverse datasets. Recent strategic moves, such as the acquisition of OpenApp, have expanded IQVIA's capabilities in developing registries for rare and chronic disease areas. Additionally, the company has partnered with Alibaba Cloud to deliver solutions in China, reinforcing its commitment to strengthening its presence in emerging markets. With operations in over 100 countries and strong connections to pharmaceutical, medical technology, and public health entities, IQVIA's patient registry offerings play a crucial role in accelerating evidence generation, optimizing treatment, and improving health system performance.

For more information, Inquire Now!

Related Reports:

Population Health Management Market

Medical Billing Market

Healthcare IT Market

Healthcare Analytics Market

Healthcare Cloud Computing Market

Get access to the latest updates on Patient Registry Software Companies and Patient Registry Software Market Size

About MarketsandMarkets:

MarketsandMarkets has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore, which integrates research and provides ecosystem-wide visibility into revenue shifts.

To find out more, visit www.MarketsandMarkets.com or follow us on Twitter , LinkedIn and Facebook .

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/

Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/patient-registry-software-market-worth-3-61-billion-by-2030-with-9-8-cagr--marketsandmarkets-302512919.html

© 2025 PR Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.